Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuromuscular and neurological diseases. The company's primary asset is Firdapse (amifampridine), the only FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder affecting approximately 3,000 patients in the US. With zero debt, 86% gross margins, and 33% net margins, Catalyst operates a highly profitable orphan drug franchise with limited direct competition.
Catalyst generates revenue through direct sales of Firdapse to specialty pharmacies and distributors serving LEMS patients. The orphan drug designation provides 7-year market exclusivity (granted 2018), premium pricing power due to lack of alternatives, and favorable reimbursement from commercial and government payers. With minimal manufacturing complexity (small molecule oral tablet) and low sales force requirements (highly targeted rare disease prescriber base of ~200-300 neuromuscular specialists), the company achieves exceptional operating leverage. The 86% gross margin reflects low cost of goods, while 40% operating margins demonstrate efficient commercial infrastructure relative to revenue scale.
Firdapse patient enrollment numbers and quarterly prescription volume trends
Pricing actions and average net revenue per patient metrics
Pipeline development updates for label expansion or new indications (e.g., MuSK-MG, congenital myasthenic syndromes)
Competitive threats from generic amifampridine or alternative LEMS therapies
Capital allocation decisions (share buybacks, M&A, pipeline investments given $200M+ annual FCF)
Orphan drug exclusivity expiration (2025 for initial LEMS indication) opens door to generic competition, though 3,4-DAP formulation complexity and small market size may deter generic entry
Drug pricing reform targeting high-cost rare disease therapies could pressure net pricing through mandatory rebates or negotiation provisions under Medicare
Single-product dependency creates binary risk if safety issues, manufacturing problems, or competitive alternatives emerge
Jacobus Pharmaceutical's 3,4-DAP (compounded amifampridine) remains available through compassionate use, creating pricing benchmark pressure
Potential development of novel LEMS therapies (monoclonal antibodies, gene therapies) by larger biotechs could disrupt market
Limited pipeline diversification means failure to expand into adjacent indications leaves company vulnerable to single-product obsolescence
Minimal financial risk given zero debt and 6.62x current ratio indicating substantial liquidity
Capital allocation risk if management pursues dilutive M&A or fails to efficiently deploy $200M+ annual FCF generation
Concentration of cash assets creates opportunity cost if not deployed into value-creating investments or returned to shareholders
low - Rare disease treatments for chronic conditions exhibit minimal correlation to GDP or consumer discretionary spending. LEMS patients require continuous therapy regardless of economic conditions, and insurance/Medicare coverage insulates demand from out-of-pocket cost sensitivity. The 3,000-patient addressable market is clinically defined rather than economically driven.
Rising rates create modest headwinds through higher discount rates applied to future cash flows, compressing valuation multiples for high-margin growth stocks. However, with zero debt and $200M annual FCF generation, Catalyst has no financing cost exposure. The company benefits from higher yields on its substantial cash position (estimated $400M+ given 6.62x current ratio and minimal debt). Rate sensitivity is primarily valuation-driven rather than operational.
minimal - Zero debt/equity ratio eliminates refinancing risk. Revenue is derived from creditworthy payers (commercial insurers, Medicare/Medicaid) with established reimbursement pathways for orphan drugs. Specialty pharmacy distribution model involves limited direct credit exposure to end patients.
growth - The 23.5% revenue growth, 129.5% net income growth, and 106% EPS growth attract growth investors seeking high-margin specialty pharma exposure. However, the 8% FCF yield and potential for capital returns also appeal to value-oriented investors. The orphan drug model with predictable recurring revenue attracts quality-focused long-term holders. Limited institutional ownership in small-cap biotech creates opportunity for fundamental-driven hedge funds.
moderate-to-high - As a $3.0B market cap single-product biotech, the stock exhibits elevated volatility around clinical/regulatory catalysts, earnings surprises, and sector rotation. Beta likely exceeds 1.0 given biotech sector correlation. The 5.9% 1-year return versus 20.1% 6-month return demonstrates momentum-driven volatility. However, established commercial revenue and profitability reduce volatility versus pre-revenue biotechs.
